Updated hourlyHourly refreshWed, Oct 28, 2026
Press Release Database
Recent press releases, indexed by topic.
AI · Healthcare
The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging populations. Advanced diagnostics, AI, targeted therapies, superficial radiation therapy and electronic brachytherapy are improving early detection and outcomes. North America leads the market, followed by Europe, while Asia-Pacific is expanding rapidly. Key players include Amgen, Regeneron, Almirall and Boehringer Ingelheim. FDA-approved Libtayo is also strengthening treatment options for cutaneous squamous cell carcinoma.
The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging populations. Advanced diagnostics, AI, targeted therapies, superficial radiation therapy and electronic brachytherapy are improving early detection and outcomes. North America leads the market, followed by Europe, while Asia-Pacific is expanding rapidly. Key players include Amgen, Regeneron, Almirall and Boehringer Ingelheim. FDA-approved Libtayo is also strengthening treatment options for cutaneous squamous cell carcinoma.
Aug 31 · 09:03·GlobeNewswire
AI · Healthcare
The global palmoplantar pustulosis market is expanding as awareness, diagnosis rates and demand for targeted biologic therapies increase. Advances in IL-23 and IL-36 research, precision medicine, biomarker discovery and AI-assisted diagnostics are accelerating treatment development. Topical therapies remain central to mild cases, while systemic agents and biologics support moderate-to-severe disease management. Growth across North America, Europe and Asia-Pacific is reinforced by clinical trials, regulatory approvals and pharmaceutical R&D, despite high treatment costs and limited access in developing regions.
The global palmoplantar pustulosis market is expanding as awareness, diagnosis rates and demand for targeted biologic therapies increase. Advances in IL-23 and IL-36 research, precision medicine, biomarker discovery and AI-assisted diagnostics are accelerating treatment development. Topical therapies remain central to mild cases, while systemic agents and biologics support moderate-to-severe disease management. Growth across North America, Europe and Asia-Pacific is reinforced by clinical trials, regulatory approvals and pharmaceutical R&D, despite high treatment costs and limited access in developing regions.
Aug 31 · 09:03·GlobeNewswire
Healthcare · Biotech & pharma
The global cancer anorexia market is expanding as rising cancer prevalence drives demand for effective anorexia and cachexia treatments. Drug development is advancing across appetite stimulants, ghrelin mimetics, myostatin inhibitors, biologics, hormonal and combination therapies. Precision medicine and nutritional support are also gaining momentum. However, limited efficacy, side effects, high treatment costs, reimbursement barriers and a lack of standardized clinical guidelines remain key challenges. Pharmaceutical and biotech companies are pursuing targeted solutions to reduce muscle wasting, improve appetite and enhance cancer patients’ quality of life.
The global cancer anorexia market is expanding as rising cancer prevalence drives demand for effective anorexia and cachexia treatments. Drug development is advancing across appetite stimulants, ghrelin mimetics, myostatin inhibitors, biologics, hormonal and combination therapies. Precision medicine and nutritional support are also gaining momentum. However, limited efficacy, side effects, high treatment costs, reimbursement barriers and a lack of standardized clinical guidelines remain key challenges. Pharmaceutical and biotech companies are pursuing targeted solutions to reduce muscle wasting, improve appetite and enhance cancer patients’ quality of life.
Aug 31 · 09:01·GlobeNewswire
Finance · AI
Opportunities include ASU compliance training, revenue recognition advisory, implementation planning, AI-enabled accounting, digital transformation, and industry-specific reporting support for biotech, pharma, and med-tech companies.
Opportunities include ASU compliance training, revenue recognition advisory, implementation planning, AI-enabled accounting, digital transformation, and industry-specific reporting support for biotech, pharma, and med-tech companies.
Aug 31 · 08:58·GlobeNewswire
Finance · Healthcare
REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) prefilled syringe and autoinjector for subcutaneous administration.
Aug 31 · 08:30·GlobeNewswire
Finance · Healthcare
Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL, Calif., Aug. 30, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and...
Aug 31 · 06:00·PR Newswire
Healthcare · Medical devices
Stryker, a global leader in medical technologies, announced a strategic partnership with the Indian Association of Gynaecological Endoscopists (IAGE) ...
Aug 31 · 04:45·Stryker
Healthcare
MUNICH, Aug. 31, 2026 -- The European Society of Cardiology Congress (ESC Congress 2026), one of the world's most influential academic gatherings in cardiovascular medicine, officially kicked off today in Munich, Germany. Huawei showcased its latest innovations in health and...
Aug 31 · 04:23·PR Newswire
Healthcare · Biotech & pharma
10XB-101 is a Novel Potential Best-in-Class Injectable Drug Being Developed for Focal Fat Reduction and Body Contouring
Aug 31 · 02:00·GlobeNewswire
Healthcare
Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting
Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting
Aug 31 · 00:00·GlobeNewswire
Healthcare
VB Health is leading the supplement industry in transparency and scientific testing by publicly releasing their COA data.
Aug 30 · 20:55·GlobeNewswire
Finance · Healthcare
CAMBRIDGE, Mass., August 30, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease.
Aug 30 · 12:23·Business Wire